[Therapy of virginal prostatic cancer with cyproterone acetate]

52 patients with virginal carcinoma of the prostate were treated with 100 mg cyproterone acetate during an observation period of 12 to 68 months (average 38.2 months). In 7 patients (13.5%) the therapy had to be stopped because of gastrointestinal intolerability. Of 45 patients in whom a relevant clinical statement was possible 44.4% showed a progression of the disease after a period of 3 to 30 months (on average 10.8 months). 95% of these patients had carcinomas with a higher degree of malignity (GII or GIII). From this is concluded that the monotherapy of the medium- to undifferentiated carcinoma of the prostate with cyproterone acetate is to be refused in this dosage.